Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anti-Pim-1 mAb inhibits activation and proliferation of T lymphocytes and prolongs mouse skin allograft survival.

Cellular immunology·2011
Same author

Pim-1 expression and monoclonal antibody targeting in human leukemia cell lines.

Experimental hematology·2009
Same author

PIM-1-specific mAb suppresses human and mouse tumor growth by decreasing PIM-1 levels, reducing Akt phosphorylation, and activating apoptosis.

The Journal of clinical investigation·2009
Same author

MUC1 cytoplasmic tail: a potential therapeutic target for ovarian carcinoma.

Expert review of anticancer therapy·2006
Same author

The molecular basis for galalpha(1,3)gal expression in animals with a deletion of the alpha1,3galactosyltransferase gene.

Journal of immunology (Baltimore, Md. : 1950)·2006
Same author

The oncogenic serine/threonine kinase Pim-1 directly phosphorylates and activates the G2/M specific phosphatase Cdc25C.

The international journal of biochemistry & cell biology·2005
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Related Experiment Video

Updated: Jan 30, 2026

A Simple and Low-cost Assay for Measuring Ambulation in Mouse Models of Muscular Dystrophy
05:54

A Simple and Low-cost Assay for Measuring Ambulation in Mouse Models of Muscular Dystrophy

Published on: December 29, 2017

10.5K

MDX-060. Medarex.

Xiu Feng Hu1, Pei Xiang Xing

  • 1The Austin Research Institute, Austin Health, Heidelberg 3084, Victoria, Australia.

Current Opinion in Investigational Drugs (London, England : 2000)
|December 24, 2005
PubMed
Summary
This summary is machine-generated.

Medarex is developing MDX-060, an antibody therapy targeting CD30+ lymphomas like Hodgkin's disease. Early-stage clinical trials were in progress by late 2002.

More Related Videos

Assessing Functional Performance in the Mdx Mouse Model
10:32

Assessing Functional Performance in the Mdx Mouse Model

Published on: March 27, 2014

33.8K
Isometric and Eccentric Force Generation Assessment of Skeletal Muscles Isolated from Murine Models of Muscular Dystrophies
14:10

Isometric and Eccentric Force Generation Assessment of Skeletal Muscles Isolated from Murine Models of Muscular Dystrophies

Published on: January 31, 2013

33.9K

Related Experiment Videos

Last Updated: Jan 30, 2026

A Simple and Low-cost Assay for Measuring Ambulation in Mouse Models of Muscular Dystrophy
05:54

A Simple and Low-cost Assay for Measuring Ambulation in Mouse Models of Muscular Dystrophy

Published on: December 29, 2017

10.5K
Assessing Functional Performance in the Mdx Mouse Model
10:32

Assessing Functional Performance in the Mdx Mouse Model

Published on: March 27, 2014

33.8K
Isometric and Eccentric Force Generation Assessment of Skeletal Muscles Isolated from Murine Models of Muscular Dystrophies
14:10

Isometric and Eccentric Force Generation Assessment of Skeletal Muscles Isolated from Murine Models of Muscular Dystrophies

Published on: January 31, 2013

33.9K

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • CD30-positive lymphomas represent a significant group of hematologic malignancies.
  • Targeted antibody therapies offer a promising approach for treating these cancers.

Purpose of the Study:

  • To evaluate the safety and efficacy of MDX-060, a novel antibody, in patients with CD30+ lymphomas.
  • To assess the potential of MDX-060 as a treatment for Hodgkin's disease and anaplastic large cell lymphomas.

Main Methods:

  • Development of the antibody MDX-060 by Medarex.
  • Initiation of Phase I/II clinical trials to assess safety and preliminary efficacy.
  • Focus on patient populations with CD30-expressing lymphomas.

Main Results:

  • Phase I/II clinical trials were underway as of December 2002.
  • Data on safety, tolerability, and preliminary efficacy were being collected.

Conclusions:

  • MDX-060 demonstrated potential as a targeted therapy for CD30+ lymphomas.
  • Further clinical investigation was warranted based on early trial progress.